Control of mitotic exit by PP2A regulation of Cdc25C and Cdk1
- *Department of Oncological Sciences and Center for Children, Huntsman Cancer Institute, and
- ‡Division of Hematology/Oncology, Department of Pediatrics, University of Utah, Salt Lake City, UT 84112; and
- †Afdeling Biochemie, Faculteit Geneeskunde, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium
-
Communicated by Thomas J. Kelly, Memorial Sloan–Kettering Cancer Center, New York, NY, October 17, 2007 (received for review June 30, 2007)
Abstract
Inactivation of maturation-promoting factor [(MPF) Cdk1/Cyclin B] is a key event in the exit from mitosis. Although degradation of Cyclin B is important for MPF inactivation, recent studies indicate that Cdk1 phosphorylation and inactivation occur before Cyclin B degradation and, therefore, also may be important steps in the exit from mitosis. Cdk1 activity is controlled by the Cdc25C phosphatase, which is turned on at the G2/M transition to catalyze Cdk1 activation. PP2A:B56δ is a negative regulator of Cdc25C during interphase. We show here that PP2A:B56δ also regulates Cdc25C at mitosis. Failure of PP2A:B56δ to dephosphorylate Cdc25C at mitosis results in prolonged hyperphosphorylation and activation of Cdc25C, causing persistent dephosphorylation and, hence, activation of Cdk1. This constitutive activation of Cdc25C and Cdk1 leads to a delayed exit from mitosis. Consistent with Cdk1 as a major biological target of B56δ, stable knockdown and germ-line mouse KO of B56δ leads to compensatory transcriptional up-regulation of Wee1 kinase to oppose the Cdc25C activity and permit cell survival. These observations place PP2A:B56δ as a key upstream regulator of Cdk1 activity upon exit from mitosis.
Footnotes
- ¶To whom all correspondence should be addressed. E-mail: gmsdmv{at}nus.edu.sg
-
Author contributions: C.M.F. and D.M.V. designed research; C.M.F. and J.M. performed research; J.V.L. and J.G. contributed new reagents/analytic tools; C.M.F. and D.M.V. analyzed data; and C.M.F. and D.M.V. wrote the paper.
-
↵ §Present address: Cancer and Stem Cell Biology Program, Duke–National University of Singapore Graduate Medical School, 2 Jalan Bukit Merah, Singapore 169547.
-
The authors declare no conflict of interest.
-
This article contains supporting information online at www.pnas.org/cgi/content/full/0709879104/DC1.
- © 2007 by The National Academy of Sciences of the USA





